Back to Search Start Over

Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer.

Authors :
Luo, Xiaoqing
Peng, Shunli
Ding, Sijie
Zeng, Qin
Wang, Rong
Ma, Yueyun
Chen, ShiYu
Wang, Yanxia
Wang, Wei
Source :
Cancer Cell International. 1/12/2021, Vol. 21 Issue 1, p1-15. 15p.
Publication Year :
2021

Abstract

Background: Serum Deprivation Protein Response (SDPR) plays an important role in formation of pulmonary alveoli. However, the functions and values of SDPR in lung cancer remain unknown. We explored prognostic value, expression pattern, and biological function of SDPR in non-small cell lung cancer (NSCLC) and KRAS-mutant lung cancers. Methods: SDPR expression was evaluated by quantitative real-time PCR (RT-qPCR), immunohistochemistry (IHC), and Western blot on human NSCLC cells, lung adenocarcinoma tissue array, KRAS-mutant transgenic mice, TCGA and GEO datasets. Prognostic values of SDPR were evaluated by Kaplan–Meier and Cox regression analysis. Bioinformatics implications of SDPR including SDPR-combined transcription factors (TFs) and microRNAs were predicted. In addition, correlations between SDPR, immune checkpoint molecules, and tumor infiltration models were illustrated. Results: SDPR expression was downregulated in tumor cells and tissues. Low SDPR expression was an independent factor that correlated with shorter overall survival of patients both in lung cancer and KRAS-mutant subgroups. Meanwhile, ceRNA network was constructed to clarify the regulatory and biological functions of SDPR. Negative correlations were found between SDPR and immune checkpoint molecules (PD-L1, TNFRSF18, TNFRSF9, and TDO2). Moreover, diversity immune infiltration models were observed in NSCLC with different SDPR expression and copy number variation (CNV) patterns. Conclusions: This study elucidated regulation network of SDPR in KRAS-mutant NSCLC, and it illustrated correlations between low SDPR expression and suppressed immune system, unfolding a prognostic factor and potential target for the treatment of lung cancer, especially for KRAS-mutant NSCLC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14752867
Volume :
21
Issue :
1
Database :
Academic Search Index
Journal :
Cancer Cell International
Publication Type :
Academic Journal
Accession number :
148072437
Full Text :
https://doi.org/10.1186/s12935-021-01756-8